Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Estradiol/drospirenone - Bayer HealthCare Pharmaceuticals

Drug Profile

Estradiol/drospirenone - Bayer HealthCare Pharmaceuticals

Alternative Names: Angeliq; Angeliq Low Dose; Angeliq low-low; BAY-864891; E2+DRSP; E2-DRSP; Estradiol/drospirenone

Latest Information Update: 11 Apr 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals; Bayer Schering Pharma
  • Class Androstenes; Antiandrogens; Estradiol congeners; Estrenes; Hormonal contraceptives; Hormonal replacements; Oral contraceptives; Progesterone congeners; Small molecules
  • Mechanism of Action Aldosterone antagonists; Estrogen receptor agonists; Mineralocorticoid receptor antagonists; Progesterone receptor agonists; Testosterone congener inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Menopausal syndrome; Postmenopausal osteoporosis
  • Discontinued Hypertension; Pregnancy

Most Recent Events

  • 02 Feb 2015 Discontinued - Phase-II for Pregnancy (Prevention) in Germany (PO)
  • 02 Feb 2015 Launched for Menopausal syndrome in Switzerland, Mexico, Chile, Brazil, Argentina, Russia, Ukraine, Indonesia, Hong Kong, Thailand, Malaysia, Turkey, Israel, China, Canada, Australia and Philippines (PO)
  • 02 Feb 2015 Launched for Postmenopausal osteoporosis (Prevention) in Switzerland, Mexico, Chile, Brazil, Argentina, Russia, Ukraine, Indonesia, Hong Kong, Thailand, Malaysia, Turkey and Israel (PO)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top